POH06 Updates in Oncodermatology
DESCRIPTION
This session will be directed towards general dermatologists wanting more familiarity with oncodermatology. It will involve updates on therapy toxicities for patients on chemotherapy, immunotherapy, and targeted therapy. There will also be a section on considerations for patients post stem cell transplantation. Attendants will gain a better understanding of critical updates in these key areas of oncodermatology which will strengthen clinical practice. Learners will take away practical diagnostic and treatment approaches for common clinical scenarios in oncodermatology. Teaching will be substantiated with representative cases as well as relevant literature.
LEARNING OBJECTIVES
Describe, diagnose, and manage the cutaneous adverse events that occur in patients on targeted therapy, chemotherapy, and following stem cell transplant.
Discuss important updates in the diagnosis and management options of hair loss in patients with cancer.
Identify and treat the unique skin conditions relevant to patients with hematologic malignancies.
SCHEDULE
11:00 AM
Welcome and updates in management of hair loss and nail changes in patients with cancer
Brittany L. Dulmage, MD, FAAD
11:20 AM
Updates in management of GVHD
Silvina Pugliese, MD, FAAD
11:40 AM
Updates in management of EGFR-inhibitor toxicities
Parul Kathuria Goyal, MD, FAAD
DIRECTOR
Brittany L. Dulmage, MD, FAAD
The Ohio State University
SPEAKERS
Parul Kathuria Goyal, MD, FAAD
Rush University Medical Center
Silvina Pugliese, MD, FAAD
DISCLOSURES
Brittany L. Dulmage, MD, FAAD
Azitra, Inc – Investigator(Grants/Research Funding); Hoth Therapeutics – Data Safety Monitoring Board(Honoraria); Novocure – Consultant (1099 relationship)(Honoraria); Xencor – Consultant (1099 relationship)(Fees);
Parul Kathuria Goyal, MD, FAAD
No financial relationships exist with ineligible companies.
Silvina Pugliese, MD, FAAD
Exelixis – Other(No Compensation Received); Regeneron Pharmaceuticals Inc – Advisory Board(Honoraria); Veradermics – Consultant (1099 relationship)(Fees);